AbbVie is reportedly in talks to acquire a biotech company developing an experimental eczema drug for $10.9 billion in cash.
MarketWatch06/20, 11:11 PM
Related assets
Coming up for ABBV
Explore next
Latest ABBV news
FirstSquawk08/20, 09:57 AM
Piper Sandler raised its price target on AbbVie to $303 from $298.
Bloomberg08/17, 06:28 PM
Bloomberg08/03, 04:58 PM